AU2016349701B2 - Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations - Google Patents

Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations Download PDF

Info

Publication number
AU2016349701B2
AU2016349701B2 AU2016349701A AU2016349701A AU2016349701B2 AU 2016349701 B2 AU2016349701 B2 AU 2016349701B2 AU 2016349701 A AU2016349701 A AU 2016349701A AU 2016349701 A AU2016349701 A AU 2016349701A AU 2016349701 B2 AU2016349701 B2 AU 2016349701B2
Authority
AU
Australia
Prior art keywords
mscs
cells
small
young
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016349701A
Other languages
English (en)
Other versions
AU2016349701A1 (en
Inventor
Travis Block
Xiao-Dong Chen
Milos MARINKOVIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2016349701A1 publication Critical patent/AU2016349701A1/en
Application granted granted Critical
Publication of AU2016349701B2 publication Critical patent/AU2016349701B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
AU2016349701A 2015-11-04 2016-11-04 Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations Active AU2016349701B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250664P 2015-11-04 2015-11-04
US62/250,664 2015-11-04
PCT/US2016/060624 WO2017079621A1 (en) 2015-11-04 2016-11-04 Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations

Publications (2)

Publication Number Publication Date
AU2016349701A1 AU2016349701A1 (en) 2018-05-24
AU2016349701B2 true AU2016349701B2 (en) 2023-10-19

Family

ID=58662777

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016349701A Active AU2016349701B2 (en) 2015-11-04 2016-11-04 Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations

Country Status (8)

Country Link
US (1) US11802272B2 (enExample)
EP (1) EP3370740A4 (enExample)
JP (2) JP6871637B2 (enExample)
CN (1) CN108601799A (enExample)
AU (1) AU2016349701B2 (enExample)
CA (1) CA3004296A1 (enExample)
HK (1) HK1254739A1 (enExample)
WO (1) WO2017079621A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190153386A1 (en) * 2017-11-17 2019-05-23 James R. Musick Stem cell line for treatment of various medical conditions
CN113166722A (zh) 2018-10-03 2021-07-23 斯特姆生物系统有限公司 羊水细胞来源的细胞外基质及其用途
KR102639023B1 (ko) 2019-02-21 2024-02-20 스템바이오시스, 인크. 양수 세포-유래 ecm 상에서 심근세포 성숙을 위한 방법, 세포 구조, 및 약물 화합물의 심장 독성 및 전부정맥 스크리닝을 위한 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807458B2 (en) * 2003-01-30 2010-10-05 The United States Of America As Represented By The Secretary Of The Department Of Veterans Affairs Multilineage-inducible cells and uses thereof
US9155762B2 (en) * 2005-12-08 2015-10-13 University Of Louisville Research Foundation, Inc. Uses and isolation of stem cells from bone marrow
EP2535403B1 (en) 2005-12-08 2019-06-19 University Of Louisville Research Foundation, Inc. Very small embryonic-like (VSEL) stem cells and methods of isolating and using the same
US8084023B2 (en) 2007-01-22 2011-12-27 The Board Of Trustees Of The University Of Arkansas Maintenance and propagation of mesenchymal stem cells
CN102333861A (zh) * 2008-09-30 2012-01-25 路易斯维尔大学研究基金会有限公司 用于分离非常小的胚胎样(vsel)干细胞的方法
BRPI0924921A2 (pt) 2009-03-31 2015-07-07 Univ Texas Métodos de isolar células-tronco mesequimais, de promover proliferação das referidas células e de produção de tecidos diferenciados
EP2614145B1 (en) 2010-09-07 2020-12-02 The Board of Regents of The University of Texas System Tissue-specific differentiation matrices and uses thereof
WO2012135838A1 (en) * 2011-04-01 2012-10-04 University Of Louisville Research Foundation, Inc. Methods and compositions for large-scale isolation of very small embryonic-like (vsel) stem cells
CA2857545A1 (en) * 2011-11-30 2013-06-06 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
US20170335286A1 (en) 2014-10-30 2017-11-23 Stembiosys, Inc. Methods for maintaining and expanding mesenchymal stem cells on extracellular matrix coated microcarriers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Hall, S.R.R. et al., Stem Cells Translational Medicine. 2013, Vol. 2, No. 8, pages 567-578 *
Igura, K. et al., AMERICAN JOURNAL OF PHYSIOLOGY - HEART AND CIRCULATORY PHYSIOLOGY. 2013, Vol. 305, No. 9, pages H1354-H1362 *

Also Published As

Publication number Publication date
HK1254739A1 (zh) 2019-07-26
JP6871637B2 (ja) 2021-05-12
AU2016349701A1 (en) 2018-05-24
CA3004296A1 (en) 2017-05-11
CN108601799A (zh) 2018-09-28
US20180320140A1 (en) 2018-11-08
EP3370740A4 (en) 2019-05-22
US11802272B2 (en) 2023-10-31
EP3370740A1 (en) 2018-09-12
WO2017079621A1 (en) 2017-05-11
JP2018537440A (ja) 2018-12-20
JP7153951B2 (ja) 2022-10-17
JP2021105047A (ja) 2021-07-26

Similar Documents

Publication Publication Date Title
Hua et al. Comparison of different methods for the isolation of mesenchymal stem cells from umbilical cord matrix: proliferation and multilineage differentiation as compared to mesenchymal stem cells from umbilical cord blood and bone marrow
KR101507172B1 (ko) 동결된 제대조직으로부터 유래하는 생존가능한 세포
Wu et al. Age-related decline in the matrix contents and functional properties of human periodontal ligament stem cell sheets
US20220184136A1 (en) Highly functional manufactured abcb5+ mesenchymal stem cells
KR20080063406A (ko) 태반 줄기세포를 이용한 면역 조절
Bernacki et al. Isolation of human mesenchymal stem cells from bone and adipose tissue
JP7153951B2 (ja) 高齢細胞集団由来の高い分化能を有するヒト間葉系幹細胞の濃縮および増幅
S Choudhery et al. Utility of cryopreserved umbilical cord tissue for regenerative medicine
US20200270579A1 (en) Method for preparing dental pulp stem cells from cells derived from dental pulp tissue
DK2723850T3 (en) A method for culturing cells in the platelet lysate-containing medium
De Luca et al. Comparative analysis of mesenchymal stromal cells biological properties
Emnett et al. Evaluation of tissue homogenization to support the generation of GMP‐compliant mesenchymal stromal cells from the umbilical cord
Alexander et al. Stromal cells cultivated from the choroid of human eyes display a mesenchymal stromal cell (MSC) phenotype and inhibit the proliferation of choroidal vascular endothelial cells in vitro
US12391924B2 (en) Method for mesenchymal stem cell isolation and osteoblast differentiation
Bertolo et al. Comparative characterization of canine and human mesenchymal stem cells derived from bone marrow
Labusca et al. Isolation and phenotypic characterisation of stem cells from late stage osteoarthritic mesenchymal tissues
US12441984B2 (en) Isolation, preservation, and expansion of canine umbilical cord mesenchymal stromal cells
US20250152633A1 (en) Cells having improved proliferative capacity and reduced cellular senescence
Ahmad et al. Human umbilical cord blood serum, a better alternative of fetal bovine serum
Caprio et al. The Effect of Replacing Fetal Bovine Serum with Platelet Releasate on the Characterization of MSCs
Dittmer Decellularized Precision Cut Lung Slices as a model to study in vitro lung regeneration
Kim et al. Isolation and identification of mesenchymal stem cells from human mastoid bone marrow
Ma et al. Human platelet lysate produced at industrial scale for use as fetal bovine serum replacement in cell manufacturing protocols
Sheard Screening and improving the safe provision of mesenchymal stem cells in regenerative medicine: an in vitro study
Kornicka et al. Research Article The Effect of Age on Osteogenic and Adipogenic Differentiation Potential of Human Adipose Derived Stromal Stem Cells (hASCs) and the Impact of Stress Factors in the Course of the Differentiation Process

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)